Development of F-18 - Labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia

David J. Yang; Sidney Wallace; Abdallah Cherif; Chun Li; Matthew B. Gretzer; E. Edmund Kim; Donald A. Podoloff

doi:10.1148/radiology.194.3.7862981

Development of F-18 - Labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia

David J. Yang, Sidney Wallace, Abdallah Cherif, Chun Li, Matthew B. Gretzer, E. Edmund Kim, Donald A. Podoloff

Research output: Contribution to journal › Article › peer-review

177 Scopus citations

Abstract

PURPOSE: To develop a hydrophilic ligand to image tumor hypoxia at positron emission tomography (PET). MATERIALS AND METHODS: Bio-distribution of fluorine-18-labeled fluoroerythronitroimidazole (FETNIM) and F-18-labeled fluoromisonidazole (FMISO) was determined at PET and autoradiography in three mammary-tumor-bearing rats. The partition coefficient of FETNIM, FMISO, and misonidazole was determined. RESULTS: Biodistribution of F-18-labeled FETNIM at 1, 2, and 4 hours showed tumor-to-blood ratios of 2.29 ± 0.599, 2.41 ± 0.567 and 8.02 ± 2.420, respectively, and tumor-to-muscle ratios of 0.66 ± 0.267, 2.11 ± 0.347, and 5.92 ± 2.240, respectively. The tumor-to-blood count density ratio with F-18-labeled FETNIM at 4 hours after injection was significantly higher than with F-18-labeled FMISO. Autoradiographs indicated that both agents could help differentiate hypoxic versus necrotic region in the tumor. CONCLUSION: F-18-labeled FETNIM can help detect tumor hypoxia and is easier to prepare, less costly, and more hydrophilic than F-18-labeled FMISO.

Original language	English (US)
Pages (from-to)	795-800
Number of pages	6
Journal	Radiology
Volume	194
Issue number	3
DOIs	https://doi.org/10.1148/radiology.194.3.7862981
State	Published - Mar 1995

Keywords

Contrast media, comparative studies
Emission CT (ECT)
Hypoxia
Neoplasms, blood supply

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.1148/radiology.194.3.7862981

Cite this

@article{3755339d5e0e4188a157d775fe5797e0,

title = "Development of F-18 - Labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia",

abstract = "PURPOSE: To develop a hydrophilic ligand to image tumor hypoxia at positron emission tomography (PET). MATERIALS AND METHODS: Bio-distribution of fluorine-18-labeled fluoroerythronitroimidazole (FETNIM) and F-18-labeled fluoromisonidazole (FMISO) was determined at PET and autoradiography in three mammary-tumor-bearing rats. The partition coefficient of FETNIM, FMISO, and misonidazole was determined. RESULTS: Biodistribution of F-18-labeled FETNIM at 1, 2, and 4 hours showed tumor-to-blood ratios of 2.29 ± 0.599, 2.41 ± 0.567 and 8.02 ± 2.420, respectively, and tumor-to-muscle ratios of 0.66 ± 0.267, 2.11 ± 0.347, and 5.92 ± 2.240, respectively. The tumor-to-blood count density ratio with F-18-labeled FETNIM at 4 hours after injection was significantly higher than with F-18-labeled FMISO. Autoradiographs indicated that both agents could help differentiate hypoxic versus necrotic region in the tumor. CONCLUSION: F-18-labeled FETNIM can help detect tumor hypoxia and is easier to prepare, less costly, and more hydrophilic than F-18-labeled FMISO.",

keywords = "Contrast media, comparative studies, Emission CT (ECT), Hypoxia, Neoplasms, blood supply",

author = "Yang, {David J.} and Sidney Wallace and Abdallah Cherif and Chun Li and Gretzer, {Matthew B.} and Kim, {E. Edmund} and Podoloff, {Donald A.}",

year = "1995",

month = mar,

doi = "10.1148/radiology.194.3.7862981",

language = "English (US)",

volume = "194",

pages = "795--800",

journal = "Radiology",

issn = "0033-8419",

publisher = "Radiological Society of North America Inc.",

number = "3",

}

TY - JOUR

T1 - Development of F-18 - Labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia

AU - Yang, David J.

AU - Wallace, Sidney

AU - Cherif, Abdallah

AU - Li, Chun

AU - Gretzer, Matthew B.

AU - Kim, E. Edmund

AU - Podoloff, Donald A.

PY - 1995/3

Y1 - 1995/3

N2 - PURPOSE: To develop a hydrophilic ligand to image tumor hypoxia at positron emission tomography (PET). MATERIALS AND METHODS: Bio-distribution of fluorine-18-labeled fluoroerythronitroimidazole (FETNIM) and F-18-labeled fluoromisonidazole (FMISO) was determined at PET and autoradiography in three mammary-tumor-bearing rats. The partition coefficient of FETNIM, FMISO, and misonidazole was determined. RESULTS: Biodistribution of F-18-labeled FETNIM at 1, 2, and 4 hours showed tumor-to-blood ratios of 2.29 ± 0.599, 2.41 ± 0.567 and 8.02 ± 2.420, respectively, and tumor-to-muscle ratios of 0.66 ± 0.267, 2.11 ± 0.347, and 5.92 ± 2.240, respectively. The tumor-to-blood count density ratio with F-18-labeled FETNIM at 4 hours after injection was significantly higher than with F-18-labeled FMISO. Autoradiographs indicated that both agents could help differentiate hypoxic versus necrotic region in the tumor. CONCLUSION: F-18-labeled FETNIM can help detect tumor hypoxia and is easier to prepare, less costly, and more hydrophilic than F-18-labeled FMISO.

AB - PURPOSE: To develop a hydrophilic ligand to image tumor hypoxia at positron emission tomography (PET). MATERIALS AND METHODS: Bio-distribution of fluorine-18-labeled fluoroerythronitroimidazole (FETNIM) and F-18-labeled fluoromisonidazole (FMISO) was determined at PET and autoradiography in three mammary-tumor-bearing rats. The partition coefficient of FETNIM, FMISO, and misonidazole was determined. RESULTS: Biodistribution of F-18-labeled FETNIM at 1, 2, and 4 hours showed tumor-to-blood ratios of 2.29 ± 0.599, 2.41 ± 0.567 and 8.02 ± 2.420, respectively, and tumor-to-muscle ratios of 0.66 ± 0.267, 2.11 ± 0.347, and 5.92 ± 2.240, respectively. The tumor-to-blood count density ratio with F-18-labeled FETNIM at 4 hours after injection was significantly higher than with F-18-labeled FMISO. Autoradiographs indicated that both agents could help differentiate hypoxic versus necrotic region in the tumor. CONCLUSION: F-18-labeled FETNIM can help detect tumor hypoxia and is easier to prepare, less costly, and more hydrophilic than F-18-labeled FMISO.

KW - Contrast media, comparative studies

KW - Emission CT (ECT)

KW - Hypoxia

KW - Neoplasms, blood supply

UR - http://www.scopus.com/inward/record.url?scp=0028917959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028917959&partnerID=8YFLogxK

U2 - 10.1148/radiology.194.3.7862981

DO - 10.1148/radiology.194.3.7862981

M3 - Article

C2 - 7862981

AN - SCOPUS:0028917959

SN - 0033-8419

VL - 194

SP - 795

EP - 800

JO - Radiology

JF - Radiology

IS - 3

ER -

Development of F-18 - Labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this